Dossier assessment

Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V

Status
Status: Commission completed
Project no.
A26-103
Last updated

Report documents

  1. Extract of dossier assessment

    Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V

    published on
    Document type
    PDF document, 292 kB, DE, not accessible
  2. Dossier assessment

    Nerandomilast (progrediente pulmonale Fibrose) – Nutzenbewertung gemäß § 35a SGB V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-103

Dossier assessment

Indication:

Adults with progressive pulmonary fibrosis (PPF)

Result of dossier assessment:
  • Nerandomilast as add-on therapy to ongoing nintedanib therapy: hint of minor added benefit
  • Nerandomilast as add-on therapy to newly initiated nintedanib therapy or as monotherapy: added benefit not proven (no suitable data)

Project details

Project no.
A26-103
Commission
Commission awarded on 14.08.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-103

Connected Projects

  1. Dossier assessment

    Nerandomilast (idiopathic pulmonary fibrosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-104
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form